Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


25.05.2020

2 Clin Cancer Res
1 J Clin Invest
2 Lancet
1 N Engl J Med


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Clin Cancer Res

  1. HAMID O, Bruno R, Fasso M, O'Hear C, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response.
    Clin Cancer Res. 2020;26:2436.
    PubMed        

  2. GOLDSTEIN DA, Ratain MJ
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
    Clin Cancer Res. 2020;26:2435.
    PubMed        


    J Clin Invest

  3. SUCH L, Zhao F, Liu D, Thier B, et al
    Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    J Clin Invest. 2020 May 19. pii: 131572. doi: 10.1172/JCI131572.
    PubMed         Abstract available


    Lancet

  4. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed         Abstract available

  5. SULLIVAN RJ
    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.
    PubMed        


    N Engl J Med

  6. ARMSTRONG KA, Cohen JV, Shepard JO, Folch EE, et al
    Case 16-2020: A 47-Year-Old Woman with Recurrent Melanoma and Pulmonary Nodules.
    N Engl J Med. 2020;382:2034-2043.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: